Skip to main content
. 2021 Jan 27;13(2):391. doi: 10.3390/nu13020391

Table 2.

Prevalence of infections and antibiotic therapy following the administration of products in the intervention group (Proxian®) and controls (placebo).

Total (n = 32) Intervention (n = 16) Placebo (n = 16) p
Clinical manifestations of infections, n (%) ** 11(34%) 4(25%) 7(44%) 0.229
Antibiotic therapy, n (%) ** 8(25%) 2(12%) 6(37%) 0.110

** Fisher’s exact test for comparison of intervention to control group.